Immunogenicity and safety of the 9-valent human papillomavirus vaccine in Chinese females 9–45 years of age: A phase 3 open-label study
- 26 April 2022
- Vol. 40 (23) , 3263-3271
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Potential impact of a nine-valent vaccine in human papillomavirus related cervical diseaseInfectious Agents and Cancer, 2012
- Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: A randomized, double-blind, placebo-controlled trial in Chinese males and femalesVaccine, 2012
- End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of ageBritish Journal of Cancer, 2011
- Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide studyThe Lancet Oncology, 2010
- Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trialBMJ, 2010
- A Pooled Analysis of Continued Prophylactic Efficacy of Quadrivalent Human Papillomavirus (Types 6/11/16/18) Vaccine against High-grade Cervical and External Genital LesionsCancer Prevention Research, 2009
- Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trialThe Lancet, 2009
- Natural History of Genital Warts: Analysis of the Placebo Arm of 2 Randomized Phase III Trials of a Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) VaccineThe Journal of Infectious Diseases, 2009
- Impact of Baseline Covariates on the Immunogenicity of a Quadrivalent (Types 6, 11, 16, and 18) Human Papillomavirus Virus‐Like‐Particle VaccineThe Journal of Infectious Diseases, 2007
- Comparison of the Immunogenicity and Reactogenicity of a Prophylactic Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine in Male and Female Adolescents and Young Adult WomenPediatrics, 2006